Preclinical R&D Services for Pancreatitis

Ace Therapeutics overcomes critical challenges in pancreatitis therapeutic development by offering tailored preclinical solutions featuring biologically validated in vivo models and physiologically-relevant in vitro models. All solutions optimized to accelerate and de-risk your drug development pipeline from discovery.

Introduction to Pancreatitis

Pancreatitis, a progressive inflammatory condition of the pancreas, presents as acute (AP) or chronic (CP) forms. Characteristic manifestations include:

• Intractable epigastric pain with radiation to the back
• Malabsorption-induced steatorrhea (oily, foul-smelling stools)
• Endocrine insufficiency from β-cell loss

Fig .1 Ethiopathology of different types of autoimmune pancreatitis. (Gallo C, et al., 2024)

Custom Pancreatitis Research Models

At Ace Therapeutics, we continuously refine our proprietary modeling platforms through ongoing technology innovation to meet scientific standards for preclinical investigation.

Pancreatitis Drug Development Services

Drug Target Identification and Validation Services

• Transcriptomics and Single Cell Sequencing
  Our integrated transcriptomics and single-cell RNA platform helps clients elucidate dysregulated molecular pathways in pancreatitis pathogenesis, facilitating the discovery and validation of novel molecular targets for therapeutic intervention.
• Metabolomics Analysis
  Leveraging high-resolution metabolomic profiling, we decode the complex metabolic derangements underlying pancreatitis progression, from pathological trypsinogen activation to mitochondrial dysfunction, while simultaneously assessing targeted therapeutic strategies including calcium channel modulation and oxidative stress mitigation.
• Microbiome Analysis
  Capitalizing on established links between gut microbiota dysbiosis and pancreatic necrosis progression, our specialized microbial discovery platform enables high-throughput screening and mechanistic characterization of next-generation pancreatitis therapeutics.

Drug Screening and Discovery Services

• Drug Screening in Pancreatic Alveolar Cell Models
  We establish translational screening platforms using primary mouse and human pancreatic acinar cells. These cell models enable quantitative assessment of drug candidates' efficacy in regulating premature trypsinogen activation and attenuating disease progression, providing clinically relevant data for pancreatitis drug development.
• Drug Screening in Inflammation and Necrosis Model Screening
  Leveraging standardized macrophage models (RAW264.7/THP-1), we quantify drug-mediated modulation of NLRP3 inflammasome activation through sensitive IL-1β secretion kinetics analysis, guiding development of next-generation anti-inflammatory therapies for pancreatitis.
• Pancreatic Enzyme Inhibition Assay Screening
  We employ a specialized screening system to identify compounds that protect against pancreatic autodigestion by systematically evaluating their inhibitory effects on key digestive enzymes through quantitative trypsin/lipase activity assays, enzymatic kinetic profiling, and cellular protection models that recapitulate pathological autoactivation cascades.

Preclinical Drug Development Services

• In Vitro Drug Efficacy Analysis
  Our standardized AR42J acinar cell models, utilizing cerulein or bile acid stimulation, enable robust preclinical evaluation of therapeutic candidates through quantitative assessment of cellular damage, inflammatory response, and apoptotic activation, providing comprehensive mechanistic insights for pancreatitis drug development.
• Drug Evaluation in Acute Pancreatitis (AP) Models
  Using well-characterized rodent models of pancreatitis (e.g., cerulein- or L-arginine-induced), we offer comprehensive phenotypic characterization including pancreatic enzyme profiling (quantitative serum amylase/lipase activity), tissue pathology evaluation (standardized histopathological edema scoring), and systemic inflammation monitoring (IL-1β and TNF-α level quantification).
• Drug Evaluation in Chronic Pancreatitis (CP) Models
  Our DBTC-induced chronic pancreatitis models can be used to evaluate efficacy of anti-fibrotic drug through longitudinal evaluation of fibrotic progression (α-SMA immunohistochemistry and collagen deposition analysis), exocrine function assessment (dynamic amylase secretion capacity testing), and ductal remodeling characterization (quantitative histomorphometric analysis of ductal structures).

Backed by a specialized team with deep expertise in pancreatology and hepatobiliary diseases, Ace Therapeutics provides customized drug development solutions to clients' pancreatitis project requirements. If you would like to learn more about our services, please feel free to contact us.

Reference

1. Gallo, C.; et al. Autoimmune pancreatitis: Cornerstones and future perspectives. World J Gastroenterol. 2024, 30(8):817-832.

Our products and services are for research use only and can not be used for diagnostic or other purposes.